Please login to the form below

Not currently logged in
Email:
Password:

Kisplyx

This page shows the latest Kisplyx news and features for those working in and with pharma, biotech and healthcare.

NICE gives green light to Ipsen's Cabometyx

NICE gives green light to Ipsen's Cabometyx

Meanwhile, NICE is in the process of assessing Eisai’s Kisplyx (lenvatinib) - approved by European regulators in 2016 as a second-line combination treatment for advanced RCC, guidance from England’s

Latest news

  • Eisai wins EU licence for kidney cancer drug Kisplyx Eisai wins EU licence for kidney cancer drug Kisplyx

    Under brand name Lenvima, Kisplyx was granted US marketing authorisation in May this year, the drug having received breakthrough and priority review status by the FDA. ... Analysts are now suggesting that with Kisplyx's approval in two key markets, plus

  • HIV prevention pill heads July CHMP recommendations HIV prevention pill heads July CHMP recommendations

    Gilead’s Truvada given positive opinion alongside Ipsen Pharma’s Cabometyx and Eisai’s Kisplyx. ... The panel also recommended approval of two targeted kidney cancer medicines - Ipsen Pharma's Cabometyx (cabozantinib) and Eisai's Kisplyx (lenvatinib

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

AI and genomics: a revolution in drug discovery and development
...
Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....

Infographics